Evidence map›Paper›PMID 39808276›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025

Vitritis following intravitreal faricimab: a retrospective monocentric analysis.

Alexandre Bourdin, Salomon Yves Cohen, Sylvia Nghiem-Buffet, Jerome Smadja, Michel Paques, Franck Fajnkuchen, Sarah Mrejen

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexandre Bourdin15-20 National Ophthalmologic Center, Paris, France.
Salomon Yves CohenOphthalmic Center for Imaging and Laser, 11 Rue Antoine Bourdelle, Paris, 75015, France. sycsyc75@gmail.com.ORCID http://orcid.org/0000-0003-1181-4379
Sylvia Nghiem-BuffetOphthalmic Center for Imaging and Laser, 11 Rue Antoine Bourdelle, Paris, 75015, France.
Jerome SmadjaLongjumeau Ophthalmologic Center, Longjumeau, France.
Michel Paques15-20 National Ophthalmologic Center, Paris, France.
Franck FajnkuchenOphthalmic Center for Imaging and Laser, 11 Rue Antoine Bourdelle, Paris, 75015, France.
Sarah Mrejen15-20 National Ophthalmologic Center, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIntravitreal injections of anti-VEGF agents are considered as safe, with a very low rate of intraocular inflammations (IOI). Faricimab is a novel intravitreal bispecific antibody targeting both VEGF-A and angiopoietin-Tie2 independently. Despite a safe profile in randomized clinical trials, several real-life studies have reported cases of IOI. The aim of this monocentric study was to report the incidence and clinical course of intraocular inflammation following intravitreal faricimab injections.

methodsA retrospective analysis was performed in our tertiary care center, based on the observation of cases between December 1, 2023 and April 30, 2024. The incidence of intraocular inflammation occurring following faricimab injections compared to other anti-VEGF agents and dexamethasone implants was assessed over the study period.

resultsIntraocular inflammation was observed in 11 eyes of seven patients, and presented as isolated, painless anterior uveitis with retrocorneal precipitates in three cases and vitritis associated with anterior uveitis in eight cases. The pattern of vitritis appeared distinctive, characterized by dense, grayish vitreous bands observed mainly in the peripheral fundus. The inflammatory phase persisted for 2-10 weeks, and regressed with steroid treatment. The overall incidence of IOI with faricimab was 0.87% (11 out of 1,271 injections), with vitritis specifically observed in 0.63% of cases (8 out of 1,271 injections). In contrast, of the 3,728 injections of other anti-VEGF agents administered (including 1,765 injections of aflibercept, 1,952 injections of ranibizumab) and 43 injections of dexamethasone implants, no cases of intraocular inflammation were reported.

conclusionsOur initial experience with faricimab indicates a potentially higher risk of intraocular inflammation, including a distinctive pattern of vitritis, compared to aflibercept and ranibizumab. The benefit/risk ratio should be carefully assessed, particularly in patients with monocular vision or who require simultaneous bilateral injections.

Indexed as

Visual AcuityVitreous BodyAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, BispecificFemaleFollow-Up StudiesHumansIncidenceIntravitreal InjectionsMaleMiddle AgedRetrospective StudiesTomography, Optical CoherenceVascular Endothelial Growth Factor AAngiogenesis InhibitorsAntibodies, BispecificfaricimabVascular Endothelial Growth Factor AAge-related macular degenerationComplicationsFaricimabIntravitreal injectionVitritis

Identifiers

PMID39808276

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.